International Journal of Scientific Research in Dental and Medical Sciences

International Journal of Scientific Research in Dental and Medical Sciences

Cell Lung Cancer Proliferation Downregulation by Tanshinone IIA: A Systematic Review and Meta-analysis

Document Type : Review Article

Authors
Farzad Amiri 1
Anahita Shirvani 2
Majid Hajizadeh 3
Mahsa Hajizadeh 4
Negar Eghbalifard 5
Fatemeh Rabiee 6
1 Department of Endocrinology and Diabetes, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of General Surgery, Imam Khomeini Shahriar Hospital, Tehran, Iran
3 Department of Radiology, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran
4 Pathology Department, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
5 Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
6 Department of Pharmacology and Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
10.30485/ijsrdms.2024.463909.1592
Abstract
Background and aim: The current investigation was carried out to ascertain the efficacy of Tan IIA in treating both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Material and methods: To obtain documentation and scientific evidence for the effectiveness of Tan IIA on small cell lung cancer cells articles published in international databases such as PubMed, Web of Science, Scopus, Sites Direct, Elsevier, Wiley, and the search engine Google Scholar were used. Data were analyzed using STATA software, version 17. Effect size with 95% confidence interval (CI), random effects model, and REML method were used.
Results: Seven studies were examined. Tanshinone IIA treatment downregulated SCLC proliferation by 4.8 percent (ES: 4.8 95 percent CI -0 point61, 1 point56). Results indicate that Tanshinone IIA treatment decreased NSCLC cell migration (ES: 6.2 percent, 95 percent confidence interval [CI], 1.01).
Conclusions: According to the current study, tanshinone IIA can inhibit the growth of both SCLC and NSCLC. Therefore, it may be regarded as a therapeutic option for both.
Keywords
Lung Neoplasms
Small Cell Lung Carcinoma
Tanshinone IIA Sodium Sulfonate

Subjects

[1] Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemporary Oncology/Współczesna Onkologia. 2021;25(1):45-52. https://doi.org/10.5114/wo.2021.103829.
[2] Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, Rodríguez-Martínez Á, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Translational Lung Cancer Research. 2021;10(1):506. https://doi.org/10.21037/tlcr.2020.03.40.
[3] Organization WH. Lung cancer: World Health Organization; 2023 [Available from: https://www.who.int/news-room/fact-sheets/detail/lung-cancer.
[4] Wéber A, Morgan E, Vignat J, Laversanne M, Pizzato M, Rumgay H, et al. Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040. BMJ open. 2023;13(5):e065303. https://doi.org/10.1136/bmjopen-2022-065303.
[5] Bade BC, Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clinics in chest medicine. 2020;41(1):1-24. https://doi.org/10.1016/j.ccm.2019.10.001.
[6] Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. Bmj. 2021;375. https://doi.org/10.1136/bmj.n2363.
[7] Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nature Reviews Disease Primers. 2021;7(1):3. https://doi.org/10.1038/s41572-020-00235-0.
[8] Saltos A, Shafique M, Chiappori A. Update on the biology, management, and treatment of small cell lung cancer (SCLC). Frontiers in oncology. 2020;10:1074. https://doi.org/10.3389/fonc.2020.01074.
[9] Wang K, Chen Q, Shao Y, Yin S, Liu C, Liu Y, et al. Anticancer activities of TCM and their active components against tumor metastasis. Biomedicine & Pharmacotherapy. 2021;133:111044. https://doi.org/10.1016/j.biopha.2020.111044.
[10] Chen Y, Yu M, Liu Z, Zhang Y, Li Q, Yang G. Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival: study protocol of a multicenter, randomized, single-blind, placebo-controlled trial. Trials. 2021;22:1-8. https://doi.org/10.1186/s13063-021-05407-1.
[11] Xu XQ, Deng WQ, Wang DY, Li M, Kou DL, Zhang PT. Chinese medicine treatment prolonged survival in small cell lung cancer patients: a clinical observation. Chinese journal of integrative medicine. 2021;27:496-501. https://doi.org/10.1007/s11655-020-3197-1.
[12] Zeng P, Li J, Chen Y, Zhang L. The structures and biological functions of polysaccharides from traditional Chinese herbs. Progress in molecular biology and translational science. 2019;163:423-44. https://doi.org/10.1016/bs.pmbts.2019.03.003.
[13] Zhu B, Zhang QL, Hua JW, Cheng WL, Qin LP. The traditional uses, phytochemistry, and pharmacology of Atractylodes macrocephala Koidz.: a review. Journal of Ethnopharmacology. 2018;226:143-67. https://doi.org/10.1016/j.jep.2018.08.023.
[14] Zhang W, Liu C, Li J, Lu Y, Li H, Zhuang J, et al. Tanshinone IIA: New perspective on the anti-tumor mechanism of A traditional natural medicine. The American Journal of Chinese Medicine. 2022;50(01):209-39. https://doi.org/10.1142/S0192415X22500070.
[15] Chen J, Bi Y, Chen L, Zhang Q, Xu L. Tanshinone IIA exerts neuroprotective effects on hippocampus-dependent cognitive impairments in diabetic rats by attenuating ER stress-induced apoptosis. Biomedicine & Pharmacotherapy. 2018;104:530-6. https://doi.org/10.1016/j.biopha.2018.05.040.
[16] Guo R, Li L, Su J, Li S, Duncan SE, Liu Z, et al. Pharmacological activity and mechanism of tanshinone IIA in related diseases. Drug Design, Development and Therapy. 2020:4735-48.
[17] Jiang Y, Bi Y, Zhou L, Zheng S, Jian T, Chen J. Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells. BMC Complementary Medicine and Therapies. 2024;24(1):68. https://doi.org/10.1186/s12906-024-04363-y.
[18] Qi H, Chen Z, Qin Y, Wang X, Zhang Z, Li Y. Tanshinone IIA inhibits cell growth by suppressing SIX1‑induced aerobic glycolysis in non‑small cell lung cancer cells. Oncology Letters. 2022;23(6):1-11. https://doi.org/10.3892/ol.2022.13304.
[19] Bai S, Cui S, Wen W, Leung EL, Bai J, Lin H, et al. Tanshinone IIA Suppresses Non-Small Cell Lung Cancer Through Beclin-1-Mediated Autophagic Apoptosis. Engineering. 2022;19:128-38. https://doi.org/10.1016/j.eng.2021.07.014.
[20] Gao F, Li M, Liu W, Li W. Inhibition of EGFR signaling and activation of mitochondrial apoptosis contribute to tanshinone IIA-mediated tumor suppression in non-small cell lung cancer cells. OncoTargets and therapy. 2020;13:2757-69.
[21] Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y, et al. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta Pharmaceutica Sinica B. 2015;5(6):554-63. https://doi.org/10.1016/j.apsb.2015.07.008.
[22] Zhang J, Wang J, Jiang JY, Liu SD, Fu K, Liu HY. Tanshinone IIA induces cytochrome c-mediated caspase cascade apoptosis in A549 human lung cancer cells via the JNK pathway. International journal of oncology. 2014;45(2):683-90. https://doi.org/10.3892/ijo.2014.2471.
[23] Cheng CY, Su CC. Tanshinone IIA may inhibit the growth of small cell lung cancer H146 cells by up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial membrane potential. Molecular Medicine Reports. 2010;3(4):645-50. https://doi.org/10.3892/mmr_00000310.
[24] Raso MG, Bota-Rabassedas N, Wistuba II. Pathology and classification of SCLC. Cancers. 2021;13(4):820. https://doi.org/10.3390/cancers13040820.
[25] Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. Journal of hematology & oncology. 2019;12. https://doi.org/10.1186/s13045-019-0736-3.
[26] Lin CY, Chang TW, Hsieh WH, Hung MC, Lin IH, Lai SC, et al. Simultaneous induction of apoptosis and necroptosis by Tanshinone IIA in human hepatocellular carcinoma HepG2 cells. Cell death discovery. 2016;2(1):16065. https://doi.org/10.1038/cddiscovery.2016.65.
[27] Li M, Gao F, Zhao Q, Zuo H, Liu W, Li W. Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis. Cell Death & Disease. 2020;11(5):381. https://doi.org/10.1038/s41419-020-2579-9.
[28] Liu Z, Zhu W, Kong X, Chen X, Sun X, Zhang W, et al. Tanshinone IIA inhibits glucose metabolism leading to apoptosis in cervical cancer. Oncology Reports. 2019;42(5):1893-903. https://doi.org/10.3892/or.2019.7294.
[29] Xie S, Wu Z, Qi Y, Wu B, Zhu X. The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges. Biomedicine & Pharmacotherapy. 2021;138:111450. https://doi.org/10.1016/j.biopha.2021.111450.
International Journal of Scientific Research in Dental and Medical Sciences
Volume 6, Issue 2
Spring 2024
Pages 85-90

  • Receive Date 20 April 2024
  • Revise Date 30 May 2024
  • Accept Date 16 June 2024
  • Publish Date 20 June 2024